Iomx

2 known investors

iOmx is a clinical-stage biotech company developing targeted cancer immunotherapies for common solid tumor indications, translating tumor immune evasion biology into biomarker-enabled drug programs. Its lead program, OMX-0407, is an orally available spectrum-selective inhibitor of salt-inducible kinase (SIK) identified via its iOTarg screening platform.

BiotechHealthtech